Search results for " tumour"

showing 10 items of 178 documents

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

2019

Background: Changes in the clinical subtype (CS) and intrinsic subtype (IS) between breast cancer (BC) metastases and corresponding primary tumours have been reported. However, their relationship with tumour genomic changes remains poorly characterised. Here, we analysed the association between genomic remodelling and subtype conversion in paired primary and metastatic BC samples. Methods: A total of 57 paired primary and metastatic tumours from GEICAM/2009-03 (ConvertHER, NCT01377363) study participants with centrally assessed CS (n = 57) and IS (n = 46) were analysed. Targeted capture and next-generation sequencing of 202 genes on formalin-fixed paraffin-embedded samples was performed. Th…

0301 basic medicineAdultCancer ResearchSkin NeoplasmsBioinformaticsBone NeoplasmsBreast Neoplasmsmedicine.disease_causeMetastatic tumours03 medical and health sciences0302 clinical medicineBreast cancerBreast cancermedicineBiomarkers TumorHumansProspective StudiesPAM50AgedAged 80 and overMutationIntrinsic subtypebusiness.industryHuman epidermal growth factorBrain NeoplasmsClonal architectureHigh-Throughput Nucleotide SequencingClonal remodellingMiddle Agedmedicine.diseasePrognosisGene Expression Regulation Neoplastic030104 developmental biologyOncology030220 oncology & carcinogenesisLymphatic MetastasisCancer cellMutationCancer researchFemaleNeoplasm Recurrence LocalClinical subtypeHeterogeneitybusinessHormoneFollow-Up Studies
researchProduct

Bone regeneration in the stem cell era: safe play for the patient?

2017

The past decade has seen outstanding scientific progress in the field of stem cell (SC) research and clinical application. SCs are convenient both technically and biologically: they are easy to find and to culture and they can differentiate in virtually all tissues and even in whole organs. Induced pluripotent stem cells (iPSs) are a type of pluripotent SC generated in vitro directly from mature cells through the introduction of key transcription factors. The use of iPSs, however tantalizing, poses serious safety concerns because of their genomic instability. Recently, it has been suggested that the main mechanism of SC action relies on paracrine signals. Therefore, the secretome would be p…

0301 basic medicineBone Regenerationbusiness.industryMechanism (biology)Cellular differentiationInduced Pluripotent Stem CellsCell DifferentiationParacrine signalsGeneral MedicineRisk Assessment03 medical and health sciences030104 developmental biologyInnovative TherapiesRheumatologyRisk analysis (engineering)HumansMedicinePatient SafetyStem cellCell differentiation Growth factor Induced pluripotent stem cell Risk Safety Transformation TumourigenesisInduced pluripotent stem cellbusinessBone regenerationStem Cell Transplantation
researchProduct

The Secreted Protein C10orf118 Is a New Regulator of Hyaluronan Synthesis Involved in Tumour-Stroma Cross-Talk.

2021

Simple Summary Hyaluronan is a main glycosaminoglycan in extracellular matrix with an important role in breast cancer progression. Alterations in its synthesis and size may affect tu-mour growth and metastasis. Communication between stromal and breast cancer cells consists of the secretion of factors that provoke a series of cell signalling that influence cell fate and tis-sue microenvironment, by favouring tumour cell survival and motility. Here, we present the c10orf118 protein expressed in high amounts by breast tumour cells as a new regulator in hya-luronan synthesis. This protein is found both in Golgi and secreted in the extracellular matrix, whereas its role is still unknown. The sec…

0301 basic medicineCancer ResearchChemokineBreast cancer; Estrogen receptor; Golgin104; Hyaluronan; Hyaluronan synthase 2; MCF-7; MDA-MB-231; Tumour microenvironmentMDA-MB-231Estrogen receptorBiologyHyaluronan Synthase 2lcsh:RC254-282ArticlehyaluronanGlycosaminoglycan03 medical and health scienceshyaluronan synthase 2breast cancer0302 clinical medicinemedicineSecretionCancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseCell biology030104 developmental biologyOncologyMCF-7030220 oncology & carcinogenesisCancer cellbiology.proteingolgin104MCF-7tumour microenvironmentestrogen receptorCancers
researchProduct

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

2019

Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC. Methods: The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic. Results: We performed an up-to-date critical review taking into account the…

0301 basic medicineCancer Researchmedicine.medical_specialtyAvelumabSkin NeoplasmsPrognosimedicine.medical_treatmentPembrolizumabImmune checkpoint inhibitorCochrane LibraryB7-H1 AntigenSettore MED/13 - EndocrinologiaAvelumab03 medical and health sciencesImmune checkpoint inhibitors0302 clinical medicineMerkel cell carcinomaNeuroendocrine tumoursNeuroendocrine tumourmedicineAnimalsHumansSkin NeoplasmIntensive care medicineMerkel cell carcinomabusiness.industryAnimalAntibodies MonoclonalGeneral MedicineImmunotherapymedicine.diseasePrognosisImmune checkpointBlockadeClinical trialCarcinoma Merkel Cell030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyTherapyAvelumab; Immune checkpoint inhibitors; Merkel cell carcinoma; Neuroendocrine tumours; Pembrolizumab; TherapybusinessPembrolizumabmedicine.drugHuman
researchProduct

TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: An international performance evaluation study

2021

AimNext generation sequencing (NGS) represents a key diagnostic tool to identify clinically relevant gene alterations for treatment-decision making in cancer care. However, the complex manual workflow required for NGS has limited its implementation in routine clinical practice. In this worldwide study, we validated the clinical performance of the TargetPlex FFPE-Direct DNA Library Preparation Kit for NGS analysis. Impressively, this new assay obviates the need for separate, labour intensive and time-consuming pre-analytical steps of DNA extraction, purification and isolation from formalin-fixed paraffin embedded (FFPE) specimens in the NGS workflow.MethodsThe TargetPlex FFPE-Direct DNA Libr…

0301 basic medicineLibraryComputer scienceGenomicsComputational biologylung neoplasmsDNA sequencingPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineHumansmolecular biologymolecularbiomarkers; lung neoplasms; molecular; molecular biology; pathology; tumourGene LibraryParaffin EmbeddingtumourSireClinical performancebiomarkersHigh-Throughput Nucleotide SequencingGeneral MedicineGenomicsDNA extractionParaffin embeddedlung neoplasm030104 developmental biologyWorkflow030220 oncology & carcinogenesisMutationbiomarkerpathology
researchProduct

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.

2017

The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMI…

0301 basic medicineMesotheliomamedicine.medical_specialtyInternational CooperationPleural NeoplasmsMEDLINESocio-culturaleContext (language use)Translational researchDiseaseSocial Networking03 medical and health sciences0302 clinical medicineMultidisciplinary approachMedicineHumansMesotheliomaPleural NeoplasmIntensive care medicinebusiness.industryGeneral MedicineThymus Neoplasmsmedicine.diseaseClinical trialEuropeSurvival Rate030104 developmental biologyClinical researchOncology030220 oncology & carcinogenesisSurgery; OncologySurgerybusinessDelivery of Health Caremesothelioma thymic tumours clinical trialsHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Clinical-pathological characteristics and short-term follow-up associated with proliferation, apoptosis and angiogenesis in a prospective cohort of p…

2019

We investigate the clinical and pathological features related to variations in colorectal tumour apoptosis, proliferation and angiogenesis and the influence of the latter in short-term mortality (2 years); 551 tumour samples from a prospective cohort of patients with colorectal cancer were examined and tumour biology markers were determined as follows: percentage of apoptotic cells, by the terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling technique; Ki-67 antigen, as a cell proliferation marker and density of microvessels (as a marker of angiogenesis). An increase in the percentage of cellular apoptosis is significantly related to the presence of poorly differentiated tumo…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyAngiogenesisApoptosisDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineBiomarkers TumorMedicineHumansProspective cohort studyPathologicalRC254-282AgedCell ProliferationNeovascularization PathologicCell growthbusiness.industryEndoglinColorectal tumourNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMiddle AgedPrognosis030104 developmental biologyKi-67 AntigenApoptosis030220 oncology & carcinogenesisFemalebusinessColorectal NeoplasmsFollow-Up StudiesTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
researchProduct

High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial

2018

Background: Patients with extremity and trunk wall soft tissue sarcoma (STS) with high malignancy grade and size >5 cm are at high-risk of death. This risk varies depending also on other patient and tumour features, including histologic subtype. This study investigated whether a prognostic nomogram can improve risk assessment of these patients. Methods: Data from high-risk STS patients enrolled in a randomised controlled trial investigating different perioperative chemotherapy regimens were analysed. Ten-year probability of overall survival (OS) and incidence of distant metastasis (DM) were computed using the prognostic nomogram Sarculator (pr-OS and inc-DM, respectively). Tumour response a…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyCancer ResearchAdolescentTumour responsePerioperative Care03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOutcome Assessment Health Caremedicinemedia_common.cataloged_instanceHumansChemotherapyEuropean unionSurvival ratemedia_commonAgedSoft tissue sarcomabusiness.industryChemotherapy; Choi criteria; Neoadjuvant; Prognosis; Soft tissue sarcoma; Tumour response; Oncology; Cancer ResearchSoft tissue sarcomaIncidence (epidemiology)SarcomaNomogramMiddle Agedmedicine.diseasePrognosisClinical trialSurvival RateNomograms030104 developmental biologyChoi criteriaOncology030220 oncology & carcinogenesisFemaleSarcomaNeoadjuvantRisk assessmentbusinessFollow-Up Studies
researchProduct

Predictive factors of response to mTOR inhibitors in neuroendocrine tumours

2016

Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for th…

0301 basic medicineOncologyCancer ResearchmTOR inhibitorEndocrinology Diabetes and MetabolismNeuroendocrine tumorsAntineoplastic Agent0302 clinical medicineEndocrinologyNeuroendocrine tumoursneuroendocrine tumourTreatment resistanceMTOR inhibitorsTumorMedical treatmentTOR Serine-Threonine KinasesDiscovery and development of mTOR inhibitorsResponse to treatmentPatient managementDiabetes and MetabolismNeuroendocrine TumorsOncology030220 oncology & carcinogenesisResponse to treatmentNeuroendocrine TumorHumanMTOR inhibitors; Neuroendocrine tumours; Predictors; Response to treatment; Animals; Antineoplastic Agents; Biomarkers Tumor; Diagnostic Imaging; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases; Endocrinology Diabetes and Metabolism; Oncology; Endocrinology; Cancer ResearchDiagnostic Imagingmedicine.medical_specialtyProtein Kinase InhibitorEarly detectionpredictorAntineoplastic AgentsMTOR inhibitors; Neuroendocrine tumours; Predictors; Response to treatment; Endocrinology; Oncology; Cancer Research; Endocrinology Diabetes and MetabolismBiologyNO03 medical and health sciencesmTOR inhibitors; neuroendocrine tumours; predictors; response to treatment; Animals; Antineoplastic Agents; Biomarkers Tumor; Diagnostic Imaging; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; TOR Serine-Threonine KinasesInternal medicineBiomarkers TumormedicineAnimalsHumansmTOR inhibitorsneuroendocrine tumourspredictorsresponse to treatmentProtein Kinase InhibitorsmTOR inhibitors neuroendocrine tumours predictors response to treatmentAnimalPredictorsmedicine.disease030104 developmental biologyImmunologyBiomarkersResource utilizationEndocrine-Related Cancer
researchProduct

FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.

2018

11556Background: Desmoid tumours (DTs) are monoclonal neoplasms with fibroblastic-myofibroblastic differentiation and they represent the most common extra-intestinal manifestation of familial adeno...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industrybody regions03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyLow-dose chemotherapy030220 oncology & carcinogenesisInternal medicineMonoclonalmedicineRetrospective analysisDesmoid tumoursbusinessJournal of Clinical Oncology
researchProduct